BRPI0511272A - métodos e reagentes para o tratamento de distúrbios imunoinflamatórios - Google Patents

métodos e reagentes para o tratamento de distúrbios imunoinflamatórios

Info

Publication number
BRPI0511272A
BRPI0511272A BRPI0511272-9A BRPI0511272A BRPI0511272A BR PI0511272 A BRPI0511272 A BR PI0511272A BR PI0511272 A BRPI0511272 A BR PI0511272A BR PI0511272 A BRPI0511272 A BR PI0511272A
Authority
BR
Brazil
Prior art keywords
pathway
treatment
methods
immunoinflammatory disorders
reagents
Prior art date
Application number
BRPI0511272-9A
Other languages
English (en)
Inventor
Palaniyandi Manivasakam
Edward Roydon Jost-Price
Jane Staunton
Curtis Keith
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0511272A publication Critical patent/BRPI0511272A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODOS E REAGENTES PARA O TRATAMENTO DE DISTúRBIOS IMUNOINFLAMATóRIOS. A presente invenção envolve o tratamento, prevenção e redução de distúrbios imunoinflamatórios que envolvem a combinação de um agente que aumenta a atividade de sinal de um receptor de glucocorticóide (por exemplo, agonista do receptor de glucocorticóide) e um agente que modula a atividade de sinalização de uma ou mais vias de sinalização selecionadas da via de NF-KB, via de NFAT, via de AP-1, e via de EIk-1 tal que a secreção ou produção de citocina pró-inflamatória, ou qualquer outra resposta inflamatória, é reduzida. Além disso, métodos de triagem são fornecidos para a identificação de compostos candidatos e estratégias úteis para o tratamento, prevenção ou redução de tais condições.
BRPI0511272-9A 2004-05-17 2005-05-16 métodos e reagentes para o tratamento de distúrbios imunoinflamatórios BRPI0511272A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57175704P 2004-05-17 2004-05-17
PCT/US2005/017117 WO2005115455A2 (en) 2004-05-17 2005-05-16 Methods and reagents for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
BRPI0511272A true BRPI0511272A (pt) 2007-12-04

Family

ID=35451412

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511272-9A BRPI0511272A (pt) 2004-05-17 2005-05-16 métodos e reagentes para o tratamento de distúrbios imunoinflamatórios

Country Status (12)

Country Link
US (1) US20050271661A1 (pt)
EP (1) EP1781267A4 (pt)
JP (1) JP2007538083A (pt)
CN (1) CN1980649A (pt)
AU (1) AU2005247403A1 (pt)
BR (1) BRPI0511272A (pt)
CA (1) CA2566861A1 (pt)
IL (1) IL179227A0 (pt)
MX (1) MXPA06013463A (pt)
NO (1) NO20065741L (pt)
TW (1) TW200605864A (pt)
WO (1) WO2005115455A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
WO2006060819A2 (en) * 2004-12-03 2006-06-08 The Regents Of The University Of California Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
US20080167277A1 (en) * 2006-12-29 2008-07-10 Charles Conrad Methods of treating skin disorders with caffeic acid analogs
EP2152276A4 (en) * 2007-05-09 2011-09-14 Traffick Therapeutics Inc SCREENING ASSAY FOR IDENTIFYING CORRECTORS FOR PROTEIN TRANSPORT TROUBLESHOOTING
KR101058136B1 (ko) * 2007-11-09 2011-08-24 신동헌 캡시에이트 또는 디하이드로캡시에이트의 신규한 용도
CA2724023C (en) * 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
WO2010036973A1 (en) * 2008-09-25 2010-04-01 Comgenrx, Inc. Treatment of hyperproliferative disorders using cardiac glycosides
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
WO2010120726A1 (en) 2009-04-13 2010-10-21 The Feinstein Institute For Medical Research Treatment of inflammatory diseases by inhibiting cold- inducible rna-binding protein (cirp)
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CN103160560A (zh) * 2011-12-08 2013-06-19 清华大学 11β，17α，20β，21- 四羟基孕甾-1，4-二烯-3-酮及其制备方法
CA2862492A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140275257A1 (en) * 2013-03-14 2014-09-18 Foundation for the State University of New York N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
WO2015048083A1 (en) 2013-09-24 2015-04-02 The Feinstein Institute For Medical Research Peptides inhibiting cold-inducible rna binding protein activity
WO2017192928A1 (en) * 2016-05-06 2017-11-09 Albany Medical College Treatment of rosacea with p38 and erk kinase pathway inhibitors
US20180006888A1 (en) * 2016-07-01 2018-01-04 Intel Corporation Analytically directed data collection in sensor network
JP2020505362A (ja) * 2017-01-19 2020-02-20 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 免疫炎症性皮膚障害を予防または治療するための方法および医薬組成物
CN107156163A (zh) * 2017-07-14 2017-09-15 安徽海日生物科技有限公司 一种甲基二磺隆和双氟磺草胺复配可分散油悬浮剂及其制备方法
CN113545316B (zh) * 2020-04-24 2022-05-17 中国科学院上海药物研究所 血根碱在制备trpa1通道激动剂中的应用
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
CN113876764B (zh) * 2021-10-29 2023-04-14 山东良福制药有限公司 包含维甲酸的药物组合物在制备治疗特发性血小板减少性紫癜的药物中的用途
CN117323442B (zh) * 2023-08-30 2024-05-03 广东医科大学 一种巨噬细胞靶向二氧化锰纳米系统的制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
WO2000059900A1 (en) * 1999-04-01 2000-10-12 The Board Of Trustees Of The University Of Arkansas P38mapk inhibitor and uses thereof
HRP20040102A2 (en) * 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
US20030157030A1 (en) * 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003299196A1 (en) * 2002-09-24 2004-04-23 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004058246A1 (en) * 2002-12-17 2004-07-15 Pharmagenesis, Inc. Triptolide derivatives as immunomodulator and anticancer agents
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS

Also Published As

Publication number Publication date
TW200605864A (en) 2006-02-16
WO2005115455A2 (en) 2005-12-08
NO20065741L (no) 2007-01-31
US20050271661A1 (en) 2005-12-08
MXPA06013463A (es) 2007-03-01
JP2007538083A (ja) 2007-12-27
WO2005115455A3 (en) 2006-08-10
IL179227A0 (en) 2007-03-08
EP1781267A4 (en) 2009-03-11
AU2005247403A1 (en) 2005-12-08
CN1980649A (zh) 2007-06-13
EP1781267A2 (en) 2007-05-09
CA2566861A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0511272A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP1401861A4 (en) CADS AS MODULATORS OF THE P53 PATH AND METHOD OF USE
BRPI0520165A2 (pt) placa àssea e mÉtodo para usar a placa àssea
MA29316B1 (fr) Derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
WO2000006085A3 (en) Compounds and methods
NO20052312L (no) Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin.
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
UA83850C2 (ru) Комбинация ингибитора src киназы и химиотерапевтических средств для лечения пролиферативных заболеваний
BRPI0409690A (pt) associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase
WO2003105753A3 (en) METHODS AND COMPOSITIONS FOR GRAFTING FUNCTIONAL LOOPS INTO A PROTEIN
WO2005042021A3 (de) Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.
NO20056116L (no) Tiowolframatanaloger og anvendelse av slike
Jüppner Genetic and epigenetic defects at the GNAS locus cause different forms of pseudohypoparathyroidism
EP4140479A4 (en) THERAPEUTIC AND/OR PROPHYLACTIC FOR CORONAVIRUS DISEASE 2019 (COVID-19)
Gaffen et al. Effects of dried plum on bone biomarkers in men (P01-028-19)
GB0411180D0 (en) Treatment of ballast water

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.